Asked by: Luke Pollard (Labour (Co-op) - Plymouth, Sutton and Devonport)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 4 March 2024 to Question 16241 on Spectacles: Irlen Syndrome, what financial support is available to low-income families to help fund prescription glasses for children where the cost of the prescription exceeds the £50 NHS voucher cost.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS optical vouchers are available for children to help with the cost of glasses that correct a defect in sight. There are ten optical voucher values ranging from £42.40 to £233.56, depending on the strength of the optical lenses. The cost of glasses will be set by individual optical practices and because prices can vary, we would always advise individuals to shop around.
Asked by: Bell Ribeiro-Addy (Labour - Streatham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether her Department has taken steps with NHS England to ensure that parents who have experienced stillbirth or neonatal death are (a) encouraged and (b) supported to (i) ask questions and (ii) talk about their experience as part of the NHS review of their care.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The Perinatal Mortality Review Tool (PMRT) provides robust and standardised reviews for bereaved parents about why their baby died. The tool’s aim is to also ensure local and national learning to improve care and prevent future baby deaths. All trusts and health boards across England, Wales, Scotland, and Northern Ireland are using the PMRT.
On 14 December 2023, Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries across the UK published their fifth annual PMRT report. The report found that most trusts and health boards ensure all bereaved parents were made aware of the PMRT and review process in their unit, and 95% reported that they offer parents the opportunity to share their thoughts, questions, or concerns about any aspect of their care for the review to address.
Asked by: Tim Loughton (Conservative - East Worthing and Shoreham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many Perinatal Mortality Review Tool reviews into (a) stillbirths and (b) baby deaths had an external panel member in the last year.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
This information is not held in the format requested. On 14 December 2023, Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries across the UK published their fifth annual Perinatal Mortality Review Tool report. The report presents data from the 4,111 reviews conducted between March 2022 to February 2023. The report sets out that an external member was present in 45% of reviews, which is an increase from only one in three involving an external member from the previous year. An external panel member is strongly recommended due to the importance of providing fresh eyes to support the review.
Asked by: Luke Evans (Conservative - Bosworth)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to support women with a genetic history of breast cancer to access screening services in (a) England and (b) Leicestershire.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
In Leicestershire and nationwide, women with a very high risk (VHR) of breast cancer due to family history may be offered screening earlier and more often, as part of the NHS Breast Screening Programme.
Women formally identified as eligible for VHR breast screening are referred to the National Health Service breast screening service associated with their general practice. They are eligible to be screened from the age of 25 years old upwards, and should be invited every year. The diagnostic screen includes mammography or magnetic resonance imaging, depending on age and risk criteria, and is therefore not the same as the routine breast screening service. To support screening of VHR women, a new central database is planned to ensure all referrals reach NHS breast screening services.
Asked by: Daisy Cooper (Liberal Democrat - St Albans)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has received representations from (a) healthcare professionals, (b) patient advocacy groups and (c) local authorities on discontinuing Type 1 diabetes and disordered eating services.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
My Rt hon. Friend, the Secretary of State for Health and Social Care engages with a range of external stakeholders, including discussions on Type 1 Diabetes with Disordered Eating (T1DE) services. NHS England is working closely with regional and integrated care board (ICB) level teams to ensure that informed decisions are made about the future provision of T1DE services.
Responsibility for the commissioning of T1DE services sits with the ICBs. It is the role of local ICB decision makers to consider the implications of continuing or discontinuing T1DE services, specific to each location, and including the perspectives of healthcare professionals, patient advocacy groups, and local authorities.
Asked by: Peter Bottomley (Conservative - Worthing West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many pharmacies have closed in Worthing West constituency since 2019; and what assessment her Department has made of the potential impact of these closures on NHS primary care services in Worthing West constituency.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
There were 19 pharmacies in Worthing West constituency on 31 December 2023. Between 31 December 2019 and 31 December 2023, three pharmacies closed and no new pharmacies opened in Worthing West.
Access to pharmaceutical services remains good. 99 percent of the population in Worthing West live within a 20-minute walk from a pharmacy. This exceeds the national average of 80 percent. In addition, residents of Worthing West can access distance selling pharmacies that operate nationally.
It is the role of local authorities in England to undertake pharmaceutical needs assessments for their areas, every three years, to ensure provision continues to meet their population’s needs. Integrated care boards have regard to those assessments when commissioning services and where a pharmacy closure impacts on the access to services, a new contractor can apply to open a pharmacy in the area.
Asked by: Peter Bottomley (Conservative - Worthing West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of community pharmacy closures on other NHS services.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
There were 19 pharmacies in Worthing West constituency on 31 December 2023. Between 31 December 2019 and 31 December 2023, three pharmacies closed and no new pharmacies opened in Worthing West.
Access to pharmaceutical services remains good. 99 percent of the population in Worthing West live within a 20-minute walk from a pharmacy. This exceeds the national average of 80 percent. In addition, residents of Worthing West can access distance selling pharmacies that operate nationally.
It is the role of local authorities in England to undertake pharmaceutical needs assessments for their areas, every three years, to ensure provision continues to meet their population’s needs. Integrated care boards have regard to those assessments when commissioning services and where a pharmacy closure impacts on the access to services, a new contractor can apply to open a pharmacy in the area.
Asked by: Peter Gibson (Conservative - Darlington)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential merits of providing lymphaticovenous anastomosis surgery on the NHS.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
No formal assessment has been made of the potential merits of providing lymphaticovenous anastomosis surgery on the National Health Service. On 16 April 2024, the National Institute for Health and Care Excellence (NICE) published interventional procedures guidance that states that lymphovenous anastomosis during axillary dissection for preventing secondary lymphoedema in adults with breast cancer, can be used in the NHS while more evidence is generated, and that it can only be used with special arrangements for clinical governance, consent and audit, or research. The NICE’s interventional procedures guidance makes recommendations for the NHS on whether procedures are sufficiently safe and efficacious for use in routine clinical practice.
Asked by: Lilian Greenwood (Labour - Nottingham South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the effectiveness of the Care Quality Commission in enforcement of the Accessible Information Standard across the NHS.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
Compliance with the Accessible Information Standard (AIS) is not directly assured by the Care Quality Commission (CQC). However, the performance of organisations in meeting people’s needs is considered in CQC assessment and ratings. Where the CQC has information through NHS England’s AIS self-assessment framework, or other sources, that an organisation is not meeting accessible communication needs, it can use its regulatory powers.
NHS England has completed a review of the AIS to help ensure that everyone’s communications needs are met in health and care provision. An AIS self-assessment framework has been developed to support providers of National Health Service and social care services, to measure their performance against the AIS and develop improvement action plans to address gaps in implementation. The AIS self-assessment framework is designed to enable enhancements around assurance and allows organisations, commissioners, and the CQC to judge performance and compliance.
Asked by: Daisy Cooper (Liberal Democrat - St Albans)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help community pharmacies with increases in the cost of medications.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Drug Tariff, published monthly, sets out the amount that will be paid to contractors for National Health Services in England, including both product reimbursement and service remuneration.
Where pharmacies cannot purchase products at or below the Drug Tariff NHS reimbursement price, Community Pharmacy England can request that the Department reassesses the reimbursement price. If a new reimbursement price is issued within the month, this is known as a concessionary price.
In addition, from 1 April 2024, we introduced a new retrospective top-up payment for concessionary prices, providing an additional payment to contractors when the margin survey indicates that despite a concessionary price, there was an under payment.